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INTERVIEW
Dr. Haifan Lin
Han Lee and Rachel Rosenstein
Yale University School of Medicine
Dr. Haifan Lin is professor of Cell Biology at Yale University, where he studies the mecha-
nism of stem cell self-renewal in fruit flies, mice, and human cancer cells. Recently named
director of the Yale Stem Cell Center, Dr. Lin has made seminal contributions to the stem cell
field, most notably his demonstration of the stem cell niche theory using the fruit fly model,
his discovery of the PIWI/AGO gene family that is essential for stem cell division in diverse
organisms, and his recent finding of a group of small RNAs called PIWI-interacting, or piR-
NAs, which may play a crucial role in stem cell proliferation and germline development. Dr.
Lin’s work on piRNAs was recognized by Science Magazine as a top scientific breakthrough
of 2006. Recently, the Lin lab has begun exploring the role of these molecules in stem cell
division and oncogenesis.
What do you foresee as the next big
breakthrough in stem cell research
that will contribute to our under-
standing of cancer?
The next big breakthrough will come
as researchers recognize and develop the
concept of cancer stem cells. Before this,
cancerresearchersgenerallytreatedallcells
incancersasequal.Recently,however,peo-
ple found in several tissues — especially in
the hematopoietic system and now in breast
tissue and a few other tissues — that only a
smallnumberofcancercellsactuallyarevi-
vacious and malignant and are able to self-
renew, which is the hallmark of stem cells.
By saying self-renew, I’m describing the
processinwhichacelldividesintotwocells
and one of the daughter cells is identical to
itself. The mother cell will always keep an
exactcopyofherself,andtherefore,itreally
is an immortal process. So the identity of
that particular mother cell, in this case a
cancer cell,willnever belost.Andthat’sre-
ally the defining difference between a stem
cell and any other progenitor or precursor
cell.Alotofotherprogenitorcellslosetheir
ownidentity when theydivide.Theygener-
ate a number of specialized cells called dif-
ferentiated cells, and they’re done. The
cancer stem cell concept, to me, is quite
wellproveninthehematopoieticsystemfor
leukemia. People have found that a very
small number of leukemic cells have stem
cell-like properties. By saying so, the stem
cell-likepropertyisonlyrelatedtoleukemia
as a tissue. These cancer stem cells are not
equivalent to the real stem cells in the sense
thattheydon’thavethecapacitytogenerate
the normal lineages of the hematopoietic
cells. However, in cancer tissue, they be-
have like stem cells. This is important be-
cause these cells actually have lots of
peculiarfeatures.Theyaremoreresistantto
irradiation or chemical insult. In fact, there
is one kind of cancer stem cell that was just
recently discovered at Duke for gliomas, a
very vicious type of brain tumor. For that
typeofcancerstemcell,themoreinsultyou
give to it, it improves itself faster and it en-
hances DNArepair mechanisms to a higher
level. It’s almost completely, in a way,
workingagainstyourtreatment.Thesecellsare usually very difficult to get rid of, and,
therefore, cancer can reoccur — I think one
of the main reasons could be due to the exis-
tence of the cancer stem cells, which are
never eradicated during the treatment. And
now, instead of designing drugs toward
generic cancer cells, one should be able to
design drugs rationally against these stem
cells. Before that breakthrough happens in
the clinics, we need to understand what ex-
actlycancerstemcellsare,whatmakesthem
different from regular cancer cells, and what
makes them different from normal stem
cells. The next breakthrough from the stem
cell perspective and for cancer research is
understanding and characterizing cancer
stem cells, and based on this knowledge, we
then can find the targeted drugs for these
cells.
There has been recent research re-
garding the stem cell niche. For in-
stance, one can insert a perfectly fine
donor hematopoietic stem cell back
into a patient, but if the niche is
messed up, these cells, too, can be-
come cancerous. What do you think
of research into the area of the stem
cell niche?
Thatisadeeperlevelofquestion. When
I say cancer stem cells, I just descriptively
say: Any of the cells that behave like stem
cells in cancer are “cancer stem cells.” How-
ever, I didn’t explore the possible causes.
There are two possible causes. One is that
stemcellsthemselvesgobadandbecomecan-
cer stem cells.Another possible cause is that
the niche becomes malignant. Cells in the
niche may send out unnecessary signals that
make stem cells overproliferate and not dif-
ferentiate.As a result, the stem cells and any
cells that receive and respond to this kind of
malignant niche signal will become cancer
stemcells.Lotsofpeoplearedesigningdrugs
strictlyagainstcancercells,butnowyouhave
to think about the equally important target of
niche cells, which we can modulate, too.
What obstacles need to be overcome
in basic science research to advance
our understanding to the point of im-
proving current therapy? How can
stem cells be used to treat non-hema-
tologic malignancies?
The principle for treating any cancer
stem cell-derived disease or any disease due
to the overproliferation of stem cells is the
same. The hematopoietic system, being a
relatively easy model, provided the most
mature model, the paradigm for which we
can develop treatment that can be equally
applied to other solid tissues. Then what is
the problem, what are the roadblocks for
treating solid tissue stem cells and cancer
stem cells? Mainly, the problem is identify-
ing them.The field of adult tissue stem cells
is still facing a problem, what I call an “iden-
tity crisis.” We don’t quite know exactly
where the normal stem cells are, and in the
case of cancer stem cells, this concept has
not been demonstrated in a lot of cancers
yet. It’s just beginning to be demonstrated in
a few more well-studied or characterized
cancers, such as breast cancer, leukemia, and
glioma. But for most other types of cancer,
we still don’t know whether they are caused
by cancer stem cells and, if so, if cancer
stem cells are the main cause. These are the
roadblocks — this identity crisis and char-
acterizing the key genes and signaling mol-
ecules from the niche.
How have the federal rules on stem
cell lines affected progression of can-
cer stem cell research in America?
What have research institutions,
such as Yale, done to overcome the
limitations that labs face with not
being able to use federal funds for
embryonic stem (ES) cell research
(other than the previously flawed ES
cell lines approved for federal
funds)?
The cell lines are non-ideal because of
several reasons.
1. They were derived earlier, and the
technology at that time was not as good as
now.The quality of the older cell lines is not
ideal.
2. The cell lines are aged and not much
has been done to rejuvenate them.
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tem that is supported by another type of cell
called “feeder cells” that are actually from
mice. In a way, these cells are contaminated
by mouse cells. Therefore, they cannot be
used directly for clinical applications.
From these three limitations, you imme-
diately will know the roadblocks. If we
don’t have new cell lines, then you cannot
do any clinical research with stem cells, pe-
riod.And that is one of the largest impacts or
negative impacts from (President) Bush’s
regulations. There are other impacts that
manifest from this central core problem; we
need better cells that we can use in humans,
but we have neither.
How doesYale overcome this problem?
We are in a very lucky situation where the
state of Connecticut actually initiated a stem
cell support program to fund research on
non-federally approved stem cells.We don’t
suffer as much from the consequences (in
reference to Bush’s regulations) like many
other institutions in the country, which
speaks volumes to the progressive mentality
of the people in the state of Connecticut and
also the government of Connecticut vs. the
one in D.C. Because this money is coming
in this month we should be able to go ahead
and do stem cell research on non-federally
funded embryonic stem cells. Of course, our
research has been set back a few years as
compared to research in other countries.
What do the states that don’t have
state funding do?
Most states do not have state funding. I
can tell you the states that do have state fund-
ing: California, New Jersey, Maryland, New
York (there is a tri-institutional stem cell sup-
port consortium started by Harold Varmus),
and,ofcourse,Connecticut.Afewotherstates
aretryingtostartfunds,buttheyarenotthere
yet.Instatesthatdon’thavefunding,youhave
to find private donations. A small number of
researchers have managed to do that. Some
stem cell researchers have left for places like
Singapore and the United Kingdom.
Is it true that the first grant money that
comes from theConnecticut Stem Cell
Research Grants will be used for
building an infrastructure for stem cell
research?
Yes, it is true that the first grant we got
for $2.5 million called the Yale Embryonic
Core Grant will be used to build a core facil-
ity for others at Yale to use. Yale has con-
tributed money to building this facility,
which will be housed where the Amistad
building is and will be built without using
any federal money. So this is where we will
be doing stem cell research legally.
Much has been written about the
Connecticut Stem Cell Research
Grants and other states' funding of
stem cell research. How much do
these state grants contribute to total
funding? What are other possible
sources of funding?
The funding from the state cannot be
measured in its absolute dollar amount. We
have at least 43 labs that do stem cell-related
research, and all these labs are funded by
National Institutes of Health (NIH) money.
That means all these labs work on stem cells
that are allowed by the federal government.
These labs either work on approved human
ES cell lines or stem cell research, like what
my lab does, on model systems like mice, or
in flies even, or on human adult stem cells,
which the federal government does not put
restrictions on. However, every single re-
search activity at Yale that will use the new,
better type of human ES cells will be sup-
ported by the Connecticut government.This
is the unique and important contribution.
Eventually, we hope to broaden our scope
by approaching private foundations, and we
also hope that after the next elections, the
federal government will change their minds.
Currently, the House and Senate are both in
favor of stem cell research. They are just
slightly short of the two-thirds vote to over-
ride Bush’s veto.
Countries such as Singapore are
building huge biology epicenters and
are trying to attract the best stem cell
researchers from the U.S. with attrac-
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opportunities. What is your take on
this? Is Yale competing with coun-
tries like Singapore when trying to re-
cruit faculty members interested in
stem cell research here, or is Singa-
pore not considered a major player
so institutions like Yale aren’t con-
cerned about it? What about in the
future?
Yale does not compete with Singapore
for faculty members, but I am happy to see
Singapore focus on stem cell research. I was
inSingaporealittleoverayearagoforanin-
ternationalstemcellmeeting.TheSingapore
government has invested a lot of money to
attract talented people there. The Biopolis is
an impressive place. But overall, Singapore
is a small country, it is a city-country. It is
wise of them to invest in one area of re-
search, and biomedical research is what they
have chosen. I am sure they will make im-
portant contributions, but Singapore alone
will not solve all the stem cell problems —
that I can say with great confidence. If you
look at their Biopolis, there are only five in-
stitutes there, and even if all five turn into
stem cell researchcenters,it is still not to the
scale that is comparable to the activity that is
in the States. I am pretty sure they can make
breakthroughs;sometimesitjusttakesacou-
ple good people. My gut feeling is that they
can amass about 50 principle investigator-
level people doing stem cell research, and
that is quite a formidable force. They will
takeasectorbutnotthemajorityofstemcell
researchers.Anotherthingistheclinicalsys-
tem, and Singapore only has a few hospitals.
But the competition is not just from Singa-
pore, there is competition from the United
Kingdom, Japan, from countries like China;
they are all investing a lot in stem cell re-
search. In biomedical research overall, the
U.S. is absolutely the leader, but in the stem
cellfield,ifwedon’tgetouracttogether,our
leading position will quickly be lost.
There are more established stem cell
centers at other institutions, such as
Harvard, University of Connecticut,
Stanford, etc. How does Yale hope to
compete with these centers and is
there a niche in the stem cell re-
search field that Yale is hoping to fill?
That’s a very good question. I think
when I came here to meet with members of
the stem cell community atYale that was the
question I kept thinking. Harvard has a re-
ally big stem cell institute already, and it
started three years ago. Stanford has one
from three or four years ago. My friend
started one at Johns Hopkins three years
ago, and at Duke I started one two years ago.
SoYale is kind of late. However, I thinkYale
has a very important niche to occupy, in that
we can focus on the fundamental principles
of stem cells.The existing institutes, such as
Harvard and other places, emphasize trans-
lational and disease-oriented research,
which, of course, is a very important part of
stem cell research. However, that is not the
whole picture. I don’t want the Yale Stem
Cell Center to become a “me, too” situation.
I want the Yale Stem Cell Center to do
something different and important by focus-
ing on the mechanisms that control stem cell
regulation. Naturally, these contributions
will lead to clinical applications. And that
has a few advantages:
1.We will make a unique and important
contribution to the stem cell field.
2. It dovetails well with the strength of
the outstanding biomedical research com-
munity at Yale.
3. It is fitting for a leading institution
like Yale to make important discoveries on
key mechanisms.
4. It requires less investment and a
smaller operation but will still be productive.
Very often people say that basic re-
search is a long-term investment where you
need lots of money and lots of effort with
lots of people. That common wisdom is not
true for stem cell research. Stem cell re-
search is no different from other types of
basic research. Yet, if you do clinical re-
search, you need lots of investments in
building infrastructures and identifying vi-
able patients. This could easily take me five
years to do, and at the end of five years, I
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nothing else will be done using the same
amount of resources. That’s not very excit-
ing. However, by doing basic research for
five years, I am confident we will be able to
say, “Look, we recruited these great faculty
members and made these great discoveries.”
I am very grateful that the Yale community,
from the leadership to the faculty, is support-
ive of this philosophy.
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